

Cyclocarysaponins AJ, dammarane-type triterpenoid glycosides from the leaves of *Cyclocarya paliurus*

Huiting XI, Mingming YUAN, Jianhua XIE, Yuanxing WANG

Citation: Huiting XI, Mingming YUAN, Jianhua XIE, Yuanxing WANG, Cyclocarysaponins AJ, dammarane-type triterpenoid glycosides from the leaves of *Cyclocarya paliurus*, *Chinese Journal of Natural Medicines*, 2024, 22(10), 955–964. doi: 10.1016/S1875-5364(24)60646-1.

View online: [https://doi.org/10.1016/S1875-5364\(24\)60646-1](https://doi.org/10.1016/S1875-5364(24)60646-1)

Related articles that may interest you

[Triterpenoid saponins and phenylpropanoid glycoside from the roots of *Ardisia crenata* and their cytotoxic activities](#)

Chinese Journal of Natural Medicines. 2021, 19(1), 63–69 [https://doi.org/10.1016/S1875-5364\(21\)60007-9](https://doi.org/10.1016/S1875-5364(21)60007-9)

[Dammarane-type triterpenoids from *Gynostemma longipes* and their protective activities on hypoxia-induced injury in PC12 cells](#)

Chinese Journal of Natural Medicines. 2024, 22(5), 466–480 [https://doi.org/10.1016/S1875-5364\(24\)60643-6](https://doi.org/10.1016/S1875-5364(24)60643-6)

[Dammarane-type triterpenoid saponins isolated from *Gynostemma pentaphyllum* ameliorate liver fibrosis via agonizing PP2C \$\alpha\$ and inhibiting deposition of extracellular matrix](#)

Chinese Journal of Natural Medicines. 2023, 21(8), 599–609 [https://doi.org/10.1016/S1875-5364\(23\)60395-4](https://doi.org/10.1016/S1875-5364(23)60395-4)

[New triterpenoid saponins from the leaves of *Ilex chinensis* and their hepatoprotective activity](#)

Chinese Journal of Natural Medicines. 2021, 19(5), 376–384 [https://doi.org/10.1016/S1875-5364\(21\)60036-5](https://doi.org/10.1016/S1875-5364(21)60036-5)

[New tirucallane-type triterpenoids from the resin of *Boswellia carterii* and their NO inhibitory activities](#)

Chinese Journal of Natural Medicines. 2021, 19(9), 686–692 [https://doi.org/10.1016/S1875-5364\(21\)60099-7](https://doi.org/10.1016/S1875-5364(21)60099-7)

[Three new ursane-type triterpenoids from *Rosmarinus officinalis* and their biological activities](#)

Chinese Journal of Natural Medicines. 2022, 20(2), 155–160 [https://doi.org/10.1016/S1875-5364\(21\)60103-6](https://doi.org/10.1016/S1875-5364(21)60103-6)



Wechat

•Original article•

Cyclocarysaponins A–J, dammarane-type triterpenoid glycosides from the leaves of *Cyclocarya paliurus*

XI Huiting¹, YUAN Mingming², XIE Jianhua^{1*}, WANG Yuanxing^{1*}¹ State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang 330047, China;² Jiangxi Institute for Drug Control, NMPA Key Laboratory of Quality Evaluation of Traditional Chinese Patent Medicine, Jiangxi Provincial Engineering Research Center of Drug and Medical Device Quality, Nanchang 330029, China

Available online 20 Oct., 2024

[ABSTRACT] Ten previously undescribed dammarane-type triterpenoid glycosides, cyclocarysaponins A–J (1–10), were isolated from the leaves of *Cyclocarya paliurus* (Batal.) Iljinskaja. The structures of these compounds were characterized through detailed spectroscopic analysis, including 1D and 2D nuclear magnetic resonance (NMR) and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). The cytotoxic activities of all isolates were assessed against five human cancer cell lines (Bel-7402, Caski, BGC-823, A2780, and HCT-116). Of the tested compounds, compounds 1, 7, and 9 exhibited selective cytotoxicity against one or more human cancer cell lines.

[KEY WORDS] *Cyclocarya paliurus*; Juglandaceae; Triterpenoid glycosides; Cyclocarysaponin; Cytotoxic activities

[CLC Number] R284.1 **[Document code]** A **[Article ID]** 2095-6975(2024)10-0955-10

Introduction

Cyclocarya paliurus (Batal.) Iljinskaja, belonging to the Juglandaceae family, is widely distributed across Jiangxi, Guangxi, Guangdong, and Zhejiang Provinces of China. This species is classified as a medicinal and edible plant [1] and is commonly known as “sweet tea” due to its naturally sweet flavor [2]. The leaves are traditionally consumed either as green vegetables or brewed into tea [3]. In traditional Chinese medicine (TCM), *C. paliurus* is known for its therapeutic properties described as “Qingrejiedu (clearing heat and detoxification) and Shengjinzhi (promoting fluid production and relieving cough),” as documented in the ancient Chinese pharmacopeia, *Zhong Hua Ben Cao* [4]. In folk medicine, its leaves are widely used for managing conditions such as diabetes, hyperlipidemia, and hypertension [5–7], and these effects have been validated through both *in vivo* and *in vitro* studies. These pharmacological activities are attributed to the major bioactive constituents of *C. paliurus* leaves, including flavon-

oids, polysaccharides, triterpenoids, steroids, saponins, and phenolic acids [8]. CHEN *et al.* identified 210 distinct compounds within *C. paliurus*, of which triterpenoids accounted for 65.2% [9]. Therefore, research and development efforts focused on the triterpenoids from *C. paliurus* have received significant attention.

The triterpenoids isolated from *C. paliurus* include 3,4-*seco*-dammarane, dammarane, oleanane, ursane, lupinane, and taraxerane derivatives. Among these, 3,4-*seco*-dammarane triterpenoids are primarily unique to *C. paliurus*, suggesting that these distinctive compounds can serve as reliable chemotaxonomic markers for the species within the Juglandaceae family [10]. Dammarane-type and 3,4-*seco*-dammarane-type triterpenoids are also the primary contributors to the sweet taste of *C. paliurus*. For instance, the sweetness of cyclocaryosides I and A has been reported to be approximately 250 and 200 times that of sucrose, respectively [11, 12]. Dammarane triterpenoids were first isolated from *C. paliurus* in 1992 [1, 12] and are considered key characteristic constituents of the plant. A recent study described two new dammarane triterpenoid saponins isolated from the leaves of *C. paliurus* [13], and subsequent studies have referred to these compounds as cypaliurusides [14, 15]. Dammarane triterpenoids exhibit hypoglycemic [14, 16], hypolipidemic [17, 18], cytotoxicity [14, 19, 20], and anti-inflammatory activities [21].

As part of an ongoing effort to identify bioactive dammarane triterpenoids from *C. paliurus*, we isolated ten previ-

[Received on] 23-Jun.-2024

[Research funding] This study was supported by the National Natural Science Foundation of China (Nos. 31960090 and 32160562) and the State Key Laboratory of Food Science and Resources, Nanchang University (No. SKLF-ZZB-202129).

[*Corresponding author] E-mails: jhxie@ncu.edu.cn (XIE Jianhua); yuanxingwang@ncu.edu.cn (WANG Yuanxing)

These authors have no conflict of interest to declare.

ously undescribed dammarane-type triterpenoid glycosides, cyclocarysaponins A–J (**1–10**, Fig. 1), from the leaves of *Cyclocarya paliurus* (Batal) Iljinskaja. Herein, we report the isolation and structure elucidation of these new compounds, as well as an evaluation of the *in vitro* cytotoxic activities of selected isolates against human cancer cell lines: Be1-7402 (hepatocarcinoma cell line), Caski (cervical cancer cell line), BGC-823 (gastric cancer cell line), A2780 (ovarian cancer cell line), and HCT-16 (colon cancer cell line).

Results and Discussion

Structure elucidation

Compound **1** was obtained as a white amorphous powder. High-resolution time-of-flight mass spectrometry (HR-TOF-MS) analysis revealed a molecular formula of $C_{40}H_{66}O_{11}$ at m/z 745.4489 $[M + Na]^+$. The 1H nuclear magnetic resonance (NMR) spectrum of **1** in pyridine- d_5 exhibited seven methyl signals at δ_H 0.69, 0.97, 1.07, 1.24, 1.37, 1.46, and 1.84 (each 3H, s), a pair of terminal olefinic protons at δ_H 4.96 and 5.06 (each 1H, br s), two olefinic protons (δ_H 6.14 and 6.44) in a *trans* relationship ($J = 16.2$ Hz), and two sugar anomeric protons at δ_H 4.69 (1H, d, $J = 6.0$ Hz) and δ_H 4.81 (1H, d, $J = 7.8$ Hz). The ^{13}C NMR spectrum of **1** in pyridine- d_5 displayed 40 carbon signals, including four double bond signals at δ_C 143.1, 115.2, 128.8, 135.9 and two anomeric carbon signals at δ_C 102.0 and 103.3. These data demonstrated that **1** shared close structural similarity with cyclocarioside **Z**₁₁, differing primarily in the sugar types and the configuration of the hydroxyl group at C-3^[22]. Acid hydrolysis of **1** with 2 mol·L^{−1} HCl afforded a monosaccharide, which was identified as α -L-arabinopyranose by gas chromatography (GC) analysis of its trimethylsilyl L-cysteine derivatives and examination of the coupling constant of the anomeric protons. The 1H – 1H correlation spectroscopy (COSY) correlations of H-9/H-11/H-12/H-13/H-17 and H-22/H-23/H-24 confirmed the presence of the two fragments –CHCHCH₂CHCH– and –CH₂CHCH– (Figs. 2 and S8). In the heteronuclear multiple bond correlation (HMBC) spectrum (Figs. 2 and S6), correlations from the anomeric protons Ara (p)-H-1' (δ_H 4.69) to C-3 (δ_C 81.7) and Ara (p)-H-1'' (δ_H 4.81) to C-11 (δ_C 77.6) suggested that the two sugar units were attached at positions 3 and 11, respectively (Fig. 2). Additionally, HMBC cross-peaks from H-26 (δ_H 5.06, 4.96, br s) to C-24 (δ_C 135.9) and C-27 (δ_C 19.3) confirmed the attachment of the terminal double bond (–C=CH₂) at C-25. HMBs from H-21–CH₃ (δ_H 1.46, s) to C-17 (δ_C 50.9) further validated the placement of the side chain at C-17. In the nuclear Overhauser effect spectroscopy (NOESY) spectrum, interactions between H-11 and both H₃-18 and H₃-19, along with correlations between H₃-29 and both H₃-18 and H₃-19, indicated an α -orientation for the hydroxyl group at C-11 and a β -orientation for the methyl group at C-29. Additional NOESY correlations between H-5/H₃-28, H₃-28/H-3, H-5/H₃-30, and H₃-30/H-17 suggested a β -orientation for the hydroxyl group at C-3 and an α -orientation for H-17

(Fig. 3). The β -orientation of the hydroxyl group at C-20 was confirmed by the similar chemical shifts of C-17, C-20, C-21, and C-22 between **1** and cypaliuruside L^[14], further supported by the NOESY correlation between H-21 and H-17 (Fig. 3). Based on these analyses, the structure of **1** was determined to be (23*E*)-dammarane-11-*O*- α -L-arabinopyranosyl-3-*O*- α -L-arabinopyranoside and named cyclocarysaponins A.

Compound **2** was isolated as a white, amorphous powder. The HR-TOF-MS peak at m/z 787.4644 $[M + Na]^+$ indicated the molecular formula of **2** to be $C_{42}H_{68}O_{12}$ and is 42 Da more than that of **1**. The NMR spectroscopic data of **2** were almost identical to those of **1** (Table 1), except that one of the arabinopyranoses in **1** was replaced by an arabinofuranose moiety in **2** and an additional acetyl group [δ_H 1.99 (3H, s); δ_C 171.2 and 21.1] in the NMR spectrum of **2**. In the HMBC spectrum of **2**, a correlation between Ara (f)-H-1' (δ_H 5.45) and C-3 (δ_C 80.1) confirmed that the α -L-arabinofuranosyl unit is located at C-3. The long-range correlation was observed between Ara (f)-H-5' (δ_H 4.50 and 4.62) and acetyl carbonyl carbon (δ_C 171.2), indicating that the acetyl group was attached to the C-5' position of arabinose. Thus, compound **2** was determined to be (23*E*)-dammarane-11-*O*- α -L-arabinopyranosyl-3-*O*-(5'-*O*-acetyl)- α -L-arabinofuranoside and named cyclocarysaponins B.

Compound **3** was isolated as a white, amorphous powder. Its molecular formula, $C_{43}H_{70}O_{12}$, was established by HR-TOF-MS (m/z 801.4800 $[M + Na]^+$, Calcd. for 801.4765). The NMR spectroscopic data of **3** closely matched those of **2**, with the primary difference being the substitution of the arabinose unit in **2** with a quinovose in **3** (Tables 1 and 2). Acid hydrolysis of **3** with 2 mol·L^{−1} HCl yielded monosaccharides, which were identified as β -D-quinovose and α -L-arabinofuranose by GC analysis of their trimethylsilyl L-cysteine derivatives and the coupling constant of the anomeric protons. The quinovose unit was determined to be attached at C-11 of the aglycone, based on the HMBC between the H-1'' (δ_H 4.94) of quinovose and C-11 (δ_C 76.9) of the aglycone. Consequently, compound **3** was determined as (23*E*)-dammarane-11-*O*- β -D-quinovopyranosyl-3-*O*-(5'-*O*-acetyl)- α -L-arabinofuranoside and named cyclocarysaponins C.

Compound **4** was a white amorphous powder. Its molecular formula, $C_{43}H_{72}O_{12}$, was determined by HR-TOF-MS at m/z 803.4945 $[M + Na]^+$, in agreement with the NMR spectroscopic data. The NMR spectra of compound **4** closely resembled those of **3**, with differences observed primarily in the C-23 to C-27 fragment. In the HMBC spectrum of **4**, cross-peaks from Me-26 and Me-27 to each other (δ_C 18.2 and δ_C 26.3, respectively), as well as to C-25 (δ_C 131.3) and C-24 (δ_C 126.5), indicated the presence of a $\Delta^{24(25)}$ double bond. In addition, HMBs from Me-21 (δ_H 1.44) to C-17 (δ_C 50.6), C-20 (δ_C 74.4), and C-22 (δ_C 41.7) were observed. The remainder of compound **4** was confirmed by COSY, HMBC, and NOESY correlations. Thus, compound **4** was determined as dammarane-(3 β ,11 α)-11-*O*- β -D-quinovopyranosyl-3-*O*-(5'-*O*-acetyl)- α -L-arabinofuranoside and named cyclocarysapon-




Fig. 1 Chemical structures of compounds 1–10.

ins D.

Compound **5** was obtained as a white, amorphous powder, with a molecular formula C₄₂H₆₈O₁₃, as determined by HR-TOF-MS with an [M + Na]⁺ peak at *m/z* 803.4566. The NMR spectroscopic data of compound **5** closely matched those of **3**, with the primary difference being the conversion of the $\Delta^{25(26)}$ double bond in **3** to a carbonyl group (>C=O) in **5** (Tables 1 and 2). The structure of **5** was further confirmed by COSY, HMBC, and NOESY correlations. Thus, compound **5** was determined as (23*E*)-20-hydroxy-25-oxo-dammarane-11-*O*- β -D-quinovopyranosyl-3-*O*-(5'-*O*-acetyl)- α -L-arabinofuranoside and named cyclocarysaponins E.

Compound **6** was obtained as a white amorphous powder, and its molecular formula was deduced as C₄₁H₆₆O₁₃ by HR-TOF-MS. The NMR spectroscopic data of **6** closely resembled those of **5**, with the primary difference being the substitution of the quinovose unit in **5** with an arabinopyranose in **6** (Tables 1 and 2). The arabinofuranose and arabinopyranose units were linked to C-3 and C-11 of the aglycone, respectively, as confirmed by HMBCs of Ara (f)-H-1' (δ_{H} 5.45)/aglycone-C-3 (δ_{C} 80.2) and Ara (p)-H-1'' (δ_{H} 4.84)/aglycone-C-11 (δ_{C} 77.1). In addition, an HMBC was observed between Ara (f)-H-5' (δ_{H} 4.61 and 4.81) and C=O (δ_{C} 171.2). Thus, compound **6** was elucidated as (23*E*)-20-hydroxy-25-oxo-dammarane-11-*O*- α -L-arabinopyranosyl-3-*O*-(5'-*O*-acetyl)- α -L-arabinofuranoside and named cyclocarysaponins F.

Compound **7** had the molecular formula C₃₅H₅₈O₈, as deduced from the HR-TOF-MS (*m/z* 629.4033 [M + Na]⁺, Calcd. for 629.4029). The NMR spectroscopic data of **7** resembled those of **5**, except that **7** lacked one quinovose and

one acetyl group present in **5**. In the HMBC spectrum of **7**, a correlation between Qui-H-1' (δ_{H} 4.94) and C-11 (δ_{C} 77.0) indicated that the quinovose was attached at the C-11 position of the aglycone. Thus, compound **7** was determined to be (23*E*)-20-hydroxy-25-oxo-dammarane-11-*O*- β -D-quinovopyranoside and named cyclocarysaponins G.

Compound **8** was a white amorphous powder. The molecular formula C₃₇H₆₀O₁₂ was determined by HR-TOF-MS at *m/z* 719.4003 [M + Na]⁺, in agreement with the NMR spectroscopic data. Its NMR data were similar to those of **7**, suggesting that **8** possessed a dammarane-type triterpenoid skeleton with the exception of the side chain resonances. The only significant changes observed were the presence of one isolated aceto-group on C-17, which was deduced by the HMBC correlation of H-17 (δ_{H} 2.56) with Me-21 (δ_{C} 30.4), and of H-13 (δ_{H} 2.21) and H-16 (δ_{H} 1.71 and 1.90) with the ketone of C-20 (δ_{C} 211.2) (Fig. 2). Thus, compound **8** was identified as 11-*O*- β -D-quinovopyranosyl-3-*O*-(5'-*O*-acetyl)- α -L-arabinofuranoside-23,24,25,26,27-hexanor-dammarane-20-one and named cyclocarysaponins H.

Compound **9** was obtained as a white powder, and its molecular formula was determined to be C₃₀H₄₈O₈ by HR-TOF-MS *m/z* 559.3244 [M + Na]⁺ (Calcd. for C₃₀H₄₈O₈Na, 559.3247), indicating seven degrees of unsaturation. The ¹H NMR data of **9** exhibited six methyl signals at δ_{H} 0.91 (3H, s), 1.05 (3H, s), 1.37 (3H, s), 1.58 (3H, d, *J* = 6.0 Hz), 1.89 (3H, s), and 2.12 (3H, s), two terminal olefinic protons at δ_{H} 4.99 (2H, br s), an oxymethine proton at δ_{H} 4.46 (1H, m), and a glycosyl anomeric proton at δ_{H} 4.91 (1H, d, *J*_{H-1'/H-2'} = 7.8 Hz). The ¹³C NMR spectrum of **9** in pyridine-*d*₅ displayed the existence of 30 carbon signals, including those of a terminal olefinic carbon at δ_{C} 149.0 and 114.4, a carboxyl carbon sig-




Fig. 2 Key HMBC (—), ^1H - ^1H COSY (—) correlations of compounds 1–10.

nals at δ_{C} 178.6, a ketone carbon signals at δ_{C} 211.4, as well as six glycosyl carbon signals at δ_{C} 101.0, 78.6, 77.2, 76.0, 73.3, and 19.0. All these data implied that **9** was structurally similar to the known compound cypaliuruside E [14], suggesting that it is a 3,4-*seco*-dammarane type triterpenoid glycoside with variations in the side chain. HMBCs from H-17 (δ_{H} 2.68) to Me-21 (δ_{C} 30.5) and from H-13 (δ_{H} 2.25) and H-16 (δ_{H} 1.74 and 1.97) to the ketone of C-20 (δ_{C} 211.4) (Fig. 2) suggested that the side chain contains an isolated aceto-group at C-17. HMBCs from H₂-28 (δ_{H} 4.99) to C-5 (δ_{C} 52.3) and C-29 (δ_{C} 24.6), from H₃-29 (δ_{H} 1.89) to C-4 (δ_{C} 149.0), C-5 (δ_{C} 52.3), and C-28 (δ_{C} 114.4), and from H₂-2 (δ_{H} 2.63 and 3.16) to C-1 (δ_{C} 38.3) and C-3 (δ_{C} 178.6), along with ^1H - ^1H -COSY correlations between H₂-1 and H₂-2 and between H-5 and H₂-6 confirmed that the A-ring of triterpene aglycone of **9** was cleaved at positions 3 and 4, forming a carboxy group and a terminal double bond. In addition, The HMBC correlation from Qui-H-1' (δ_{H} 4.91) to C-11 (δ_{C} 75.5) indicated that the quinovose was linked at C-11. Its diagnostic NOESY correlations of H-5/H-9/H-17/H₃-30 suggested that H-5, H-9, H-17, and CH₃-30 are α -oriented (Figs. 3 and S72). The β -orientations of H-11, H-13, H₃-18, and H₃-19 were verified by the NOESY correlations of H-11/H-13/H₃-18/H₃-19. Thus, compound **9** was elucidated as 11-*O*- β -D-quinovopyranosyl-23,24,25,26,27-hexanor-3,4-*seco*dammar-20-one-4(28)-en-3-oic acid and named cyclocarysaponins I.

Compound **10** was obtained as a white amorphous powder. The molecular formula of **10** was determined to be C₃₀H₄₈O₈ by HR-TOF-MS. The NMR spectroscopic data of compound **10** were similar to those of **9**, with the primary dif-

ference being the substitution of the quinovose unit in **9** with an arabinose unit in **10** and the presence of an additional methoxy group in **10**. In the HMBC spectrum, a correlation between OCH₃ (δ_{H} 3.60) and C-3 (δ_{C} 176.9) revealed that the methoxy group was connected to C-3 of the aglycone. An HMBC correlation from Ara-H-1 (δ_{H} 4.77) to C-11 (δ_{C} 75.9) confirmed that the arabinose was attached at C-11 of the aglycone. Therefore, compound **10** was deduced as 11-*O*- α -L-arabinopyranosyl-23,24,25,26,27-hexanor-3,4-*seco*dammar-20-one-4(28)-en-3-oic acid methyl ester and named cyclocarysaponins J.

Biological activity of cyclocarysaponins A–J (1–10)

Compounds **1–10** were evaluated for their cytotoxic activities against five human tumor cell lines (Bel-7402, Caski, BGC-823, A2780, and HCT-116) with paclitaxel as a positive control. Among the tested compounds, compound **1** showed cytotoxic activities against Bel-7402 and BGC-823 cells, with IC₅₀ values of 8.52 ± 0.63 and 21.14 ± 1.45 $\mu\text{mol}\cdot\text{L}^{-1}$, respectively. Compound **7** exhibited cytotoxic activity against A2780 cells, with an IC₅₀ value of 12.82 ± 1.86 $\mu\text{mol}\cdot\text{L}^{-1}$. compound **9** showed cytotoxic activities against Bel-7402, A2780, and HCT-116 cells, with IC₅₀ values of 13.46 ± 2.27 , 10.33 ± 1.78 , and 25.23 ± 3.57 $\mu\text{mol}\cdot\text{L}^{-1}$, respectively. (Fig. 4). Additionally, the inhibitory activities of these compounds against α -glucosidase and PTP1B enzymes, as well as their inhibitory effects against nitric oxide (NO) production in RAW264.7 mouse macrophages induced by lipopolysaccharide (LPS) were also evaluated. However, none of the compounds exhibited significant inhibitory activities by these compounds at 10 $\mu\text{mol}\cdot\text{L}^{-1}$.




Fig. 3 NOESY correlations of compounds **1–10**.

Table 1 ^1H NMR data for compounds **1–10** at 600 MHz, respectively (in pyridine- d_5 , J in Hz)

No.	1	2	3	4	5	6	7	8	9	10
1	2.01, m 3.04, dt 13.6, 4.8	1.80, m 3.05, m	1.81, m 3.02, m	1.82, m 3.01, m	1.81, m 3.00, dd 3.6, 10.2	1.85, m 3.07, dt 13.2, 4.8	2.14, m 3.10, dd 4.2, 10.8	1.80, m 3.01, dd 3.6, 10.2	2.01, m 3.13, m	1.75, m 3.00, m
2	1.77, m	1.68, m 1.54, m	1.66, m 1.81, m	1.67, m 1.81, m	1.66, m 1.81, m	1.54, m 1.80, m	1.77, m 2.14, m	1.66, m 1.81, m	2.63, m 3.16, m	2.43, m 3.00, m
3	3.58, t, 3.0	3.52, t, 3.0	3.57, t, 3.0	3.57, t, 3.0	3.57, br s	3.52, t, 3.0	3.62, br s	3.56, br s		
4										
5	1.58, m	1.52, m	1.54, m	1.56, m	1.55, m	1.53, m	1.81, m	1.53, m	2.21, m	2.10, m
6	1.46, m 1.51, m	1.44, m 1.52, m	1.50, m 1.56, m	1.47, m 1.57, m	1.49, m	1.48, m	1.54, m	1.43, m 1.51, m	1.36, m 1.85, m	1.33, m 1.81, m
7	1.19, m 1.51, m	1.19, m 1.54, m	1.21, m 1.56, m	1.22, m 1.57, m	1.21, m 1.55, m	1.21, m 1.61, m	1.25, m 1.68, m	1.14, m 1.52, m	1.08, m 1.52, m	1.11, m 1.54, m
8										
9	1.88, d, 10.8	1.88, d, 10.8	1.89, d, 10.2	1.92, d, 10.8	1.88, d, 11.4	1.87, d, 10.8	2.04, d, 10.8	1.84, d, 10.8	2.08, d, 10.8	2.02, d, 10.8
10										
11	4.45, td 10.8, 4.8	4.47, td 10.2, 4.8	4.47, td 10.2, 4.8	4.45, td 10.8, 4.8	4.44, td 10.8, 4.8	4.45, td 10.8, 4.8	4.49, td 10.2, 4.8	4.41, td 10.8, 4.8	4.46, td 10.2, 4.8	4.42, m
12	1.61, m 2.99, dt 13.2, 5.6 2.14, td	1.69, m 3.04, m	1.69, m 2.99, m	1.70, m 2.95, dt 13.2, 5.6 2.16, td	1.67, m 2.95, dt 13.2, 4.8 2.09, td	1.71, m 3.02, dt 13.2, 4.8 2.08, td	1.71, m 2.97, dt 13.2, 4.8 2.14, td	1.53, m 2.56, m	1.56, m 2.61, m	1.54, m 2.64, m
13	10.2, 3.6	10.2, 3.0	10.2, 3.0	10.2, 3.0	10.8, 3.6	10.2, 3.6	11.4, 3.0	2.21, m	2.25, m	2.23, m
14										

Continued

No.	1	2	3	4	5	6	7	8	9	10
15	1.04, m 1.51, m	1.16, m 1.43, m	1.06, m 1.54, m	1.08, m 1.54, m	1.05, m 1.51, m	1.05, m 1.49, m	1.07, m 1.55, m	1.03, m 1.39, m	1.10, m 1.52, m	1.13, m 1.59, m
16	1.83, m 1.91, m	1.85, m 1.90, m	1.85, m 1.91, m	1.84, m 1.93, m	1.82, m	1.82, m	1.85, m	1.71, m 1.90, m	1.74, m 1.97, m	1.79, m 2.05, m
17	1.97, m	2.02, m	2.01, m	1.97, m	1.95, m	1.96, m	1.95, m	2.56, m	2.68, m	2.75, td, 6.6, 10.8
18	1.07, s	1.06, s	1.09, s	1.08, s	1.08, s	1.04, s	1.12, s	1.02, s	1.05, s	1.00, s
19	1.37, s	1.32, s	1.35, s	1.34, s	1.34, s	1.32, s	1.41, s	1.32, s	1.37, s	1.24, s
20										
21	1.46, s	1.47, s	1.43, s	1.44, s	1.41, s	1.43, s	1.42, s	2.08, s	2.12, s	2.25, s
22	2.53, dd, 7.8, 13.8 2.69, dd, 6.6, 13.8	2.54, dd, 7.8, 13.8 2.70, dd, 6.6, 13.8	2.51, dd, 7.8, 13.8 2.67, dd, 6.6, 13.8	1.77, m 1.89, m	2.50, dd, 8.4, 13.8 2.71, dd, 7.2, 13.8	2.54, dd, 7.8, 14.4 2.74, dd, 6.6, 13.8	2.53, dd, 7.8, 14.4 2.72, dd, 6.6, 13.8			
23	6.14, m	6.16, m	6.12, m	2.28, m 2.36, m	7.8, 16.2	7.32, dd, 7.8, 15.6	7.31, dd, 7.2, 15.6			
24	6.44, d, 16.2	6.45, d, 16.2	6.41, d, 15.6	5.31, t, 6.6, 13.8	6.36, d, 16.2	6.39, d, 16.2	6.36, d, 16.2			
25										
26	4.96, br s 5.06, br s	4.96, br s 5.07, br s	4.96, br s 5.05, br s	1.64, s	2.23, s	2.23, s	2.24, s			
27	1.84, s	1.85, s	1.84, s	1.67, s						
28	0.97, s	0.92, s	0.97, s	0.96, s	0.97, s	0.92, s	1.01, s	0.96, s	4.99, br s	4.87, br s 4.97, br s
29	1.24, s	1.24, s	1.26, s	1.26, s	1.27, s	1.24, s	1.27, s	1.26, s	1.89, s	1.80, s
30	0.69, s	0.79, s	0.80, s	0.83, s	0.78, s	0.76, s	0.87, s	0.71, s	0.91, s	0.95, s
1'	4.69, d, 6.0	5.45, d, 1.2	5.51, d, 1.2	5.52, d, 1.2	5.51, d, 1.8	5.45, d, 1.8		5.51, d, 1.8		
2'	4.25, dd, 3.6, 8.4	4.85, m	4.86, m	4.87, m	4.86, m	4.85, m		4.85, m		
3'	4.41, m	4.62, m	4.62, m	4.63, m	4.63, m	4.62, m		4.63, m		
4'	4.40, m	4.74, td, 6.6, 3.0	4.75, td, 6.6, 3.0	4.75, td, 6.6, 3.0	4.75, td, 7.2, 3.0	4.74, td, 6.6, 3.0		4.74, td, 7.2, 3.0		
5'	3.76, dd, 2.4, 12.0 4.31, m	4.81, dd, 3.6, 12.0 4.62, m	4.81, dd, 3.0, 12.0 4.62, m	4.82, dd, 3.6, 12.0 4.62, m	4.60, m 4.82, dd, 3.0, 5.4	4.61, d, 6.0 4.81, dd, 3.0, 6.0		4.61, m 4.81, dd, 3.0, 6.0		
1''	4.81, d, 7.8	4.84, d, 7.8	4.94, d, 7.8	4.91, d, 7.8	4.95, d, 7.8	4.84, d, 7.8	4.94, d, 7.8	4.84, d, 7.8	4.91, d, 7.8	4.77, d, 7.8
2''	4.06, dd, 3.6, 9.0	4.06, d, 9.0	3.94, t, 9.0	3.94, t, 8.4	3.94, t, 8.4	4.06, dd, 3.6, 9.0	3.98, dd, 8.4, 9.0	3.91, m	4.11, t, 5.4	4.12, dd, 3.0, 9.0
3''	4.37, m	4.35, t, 7.2	4.09, t, 8.4	4.10, t, 8.4	4.10, t, 8.4	4.36, t, 8.4	4.12, t, 9.0	4.09, t, 9.0	4.20, t, 9.0	4.37, m
4''	4.21, m	4.21, m	3.68, m	3.68, t, 8.4	3.67, t, 8.4	4.21, m	3.67, m	3.66, t, 9.0	3.69, t, 9.0	4.26, d, 1.8
5''	3.65, dd, 1.2, 12.6 4.29, m	3.64, d, 12.0 4.28, dd, 2.4, 12.0	3.63, m	3.61, m	3.64, m	3.66, dd, 1.8, 12.6 4.29, dd, 1.2, 12.6	3.64, m	3.59, m	3.63, m	3.63, d, 5.4 4.23, m
6''			1.61, d, 6.0	1.60, d, 6.0	1.61, d, 5.4		1.62, d, 5.4	1.60, d, 6.0	1.58, d, 6.0	
CH ₃ COO-										
CH ₃ COO-		1.99, s	1.98, s	1.99, s	1.98, s	1.98, s		1.99, s		
-OCH ₃										3.60, s

Table 2 ^{13}C NMR data for compounds **1–10** at 150 MHz, respectively (in pyridine- d_5)

No.	Cyclocarioside Z_{11}	1	2	3	4	5	6	7	8	9	10
1	35.9	36.0	36.1	36.0	36.0	36.0	36.1	35.9	36.0	38.3	38.1
2	21.7	22.2	21.8	21.9	21.9	21.9	21.9	27.5	21.9	31.3	30.9
3	79.5	81.7	80.1	80.1	80.2	80.2	80.2	75.8	80.1	178.6	176.9
4	38.2	38.5	38.3	38.4	38.4	38.4	38.3	39.1	38.4	149.0	149.0
5	51.2	51.4	51.3	51.4	51.4	51.4	51.4	50.5	51.4	52.3	52.6
6	18.6	18.7	18.7	18.8	18.8	18.8	18.7	19.0	18.7	25.8	25.8
7	36.5	36.8	36.7	36.8	36.8	36.8	36.7	37.0	36.9	35.5	35.6
8	50.8	50.9	51.1	51.1	51.1	51.1	51.0	51.1	50.5	50.9	51.0
9	54.2	54.5	54.4	54.5	54.5	54.4	54.4	54.7	54.3	44.9	45.1
10	40.2	40.4	40.4	40.4	40.4	40.4	40.5	40.6	40.4	40.8	40.8
11	77.1	77.6	77.0	76.9	77.0	77.0	77.1	77.0	76.6	75.5	75.9
12	35.0	35.0	35.0	35.2	35.3	35.2	35.0	35.2	33.1	32.5	32.5
13	41.0	41.3	41.2	41.2	41.0	41.4	41.4	41.4	43.3	43.4	43.6
14	41.6	41.9	41.9	41.9	41.9	41.9	41.9	42.0	41.9	41.4	41.6
15	31.5	31.7	31.7	31.8	31.9	31.7	31.7	31.7	31.8	31.9	32.1
16	25.9	26.1	26.1	26.2	26.1	26.2	26.2	26.2	27.2	27.1	27.4
17	50.8	50.9	51.0	51.1	50.6	51.5	51.5	51.5	54.2	54.3	54.4
18	17.3	17.5	17.6	17.6	17.6	17.6	17.6	17.7	17.5	17.0	17.3
19	16.9	17.3	17.1	17.1	17.1	17.1	17.1	17.1	17.0	20.7	21.0
20	74.7	74.8	74.9	74.9	74.4	74.8	74.8	74.9	211.2	211.4	212.6
21	27.6	27.7	27.8	27.9	27.4	27.8	27.8	27.8	30.4	30.5	30.8
22	45.1	45.3	45.1	45.2	41.7	44.5	44.5	44.7			
23	128.6	128.8	128.8	128.8	23.9	146.8	146.7	146.9			
24	135.6	135.9	135.9	135.7	126.5	134.2	134.2	134.2			
25	142.9	143.1	143.1	143.1	131.3	198.5	198.3	198.7			
26	115.1	115.2	115.2	115.2	18.2	27.4	27.3	27.4			
27	19.1	19.3	19.3	19.3	26.3						
28	23.2	23.6	23.3	23.4	23.4	23.4	23.4	23.4	23.4	114.4	114.7
29	30.0	30.4	30.3	30.4	30.4	30.4	30.2	30.5	30.4	24.6	24.8
30	17.0	17.1	17.2	17.2	17.3	17.2	17.3	17.2	16.5	16.4	16.7
1'	106.6	102.0	107.0	107.1	107.1	107.1	107.1		107.1		
2'	84.4	75.0	84.6	84.6	84.6	84.7	84.7		84.7		
3'	79.7	72.8	80.3	80.3	80.3	80.3	80.4		80.3		
4'	85.8	69.4	81.9	81.9	82.0	82.0	82.0		82.0		
5'	63.2	66.5	65.5	65.6	65.6	65.6	65.6		65.6		
1''	102.2	103.3	102.9	101.9	101.9	102.1	103.0	102.1	101.9	101.0	102.0
2''	75.6	75.2	75.2	76.0	76.0	76.1	75.2	76.1	76.0	76.0	75.3
3''	78.7	73.1	73.2	78.7	78.7	78.7	73.2	78.7	78.7	78.6	73.3
4''	78.0	70.1	70.2	77.3	77.3	77.3	70.2	77.3	77.3	77.2	70.5
5''	72.6	67.9	68.0	73.1	73.1	73.1	68.0	73.2	73.1	73.3	68.2
6''	63.8			19.1	19.1	19.1		19.1	19.1	19.0	
CH ₃ COO-			171.2	171.3	171.3	171.3	171.2		171.3		
CH ₃ COO-			21.1	21.2	21.2	21.2	21.2		21.2		
-OCH ₃											52.2

Conclusions

In summary, ten previously undescribed dammarane-type triterpenoid glycosides, cyclocarysaponins A–J (**1–10**), were isolated from the leaves of *C. paliurus*. Among these

compounds, three triterpenoid saponins containing ketocarboxyl groups at position 25 and three triterpenoid saponins with cleavages at positions C₂₂–C₂₇ were first found in *C. paliurus*. The results presented in the article contribute to ex-




Fig. 4 Cytotoxic activities of compounds **1**, **7**, and **9** against Bel-7402, BGC-823, HCT-116, and A2780 cell lines.

panding our knowledge on the chemical diversity of dammarane-type triterpenoids. Although none of the tested compounds exhibited inhibitory activities against α -glucosidase, PPT1B, or LPS-induced NO production in mouse macrophages, compounds **1**, **7**, and **9** showed moderate cytotoxic activities against one to three human cancer cell lines.

Experimental

General experimental procedures

Optical rotations were measured on a Perkin-Elmer 241 automatic digital polarimeter (Waltham, Massachusetts, USA). UV spectra were obtained on a Shimadzu UV-260 spectrophotometer (Shimadzu, Tokyo, Japan). 1D and 2D NMR spectra were recorded on a Varian Unity INOVA 600 spectrometer using pyridine-*d*₅ as solvent and tetramethylsilane (TMS) as an internal standard (Varian Company, California, USA). The UPLC-Q-TOF-MS data were obtained on an Acquity UPLC/Xevo G2 QTOF (Waters Technologies, Massachusetts, USA). GC was conducted using an Agilent Technologies 7890A instrument (Agilent, USA). Preparative high-performance liquid chromatography (HPLC) was conducted on an Agilent 1260 infinity II Prep instrument with an MWD detector, using a YMC-Pack ODS (octadecylsilyl)-A column (5 μm, 250 mm × 20 mm). Column chromatography (CC) was performed with silica gel (200–300 mesh, Qingdao Marine Chemical Inc., Qingdao, China) and ODS (50 μm, YMC, Japan). Fractions were visualized by silica gel plates sprayed with 10% H₂SO₄ ethanol solution, followed by heating. All analytical reagents were of analytical grade and purchased from Tianjin Fuyu Fine Chemical Co., Ltd., Tianjin, China.

Plant material

The leaves of *C. paliurus* (Batal.) Iljinskaja were collected from Shangrao City, Jiangxi Province, China, in September 2020 and identified by Prof. YANG Baiyun and deposited (No. YP20200911) in the herbarium of Nanchang University, China.

Extraction and isolation

The powdered dried leaves of *C. paliurus* (9.7 kg) were extracted four times with 70% EtOH under reflux (2 h each).

The combined extract was concentrated under reduced pressure to yield a dark brown residue (2.9 kg). This residue was suspended in water (60 L) and then successively partitioned with petroleum ether (3 × 60 L), EtOAc (3 × 60 L), and *n*-BuOH (3 × 60 L). The solvent from the EtOAc-soluble fraction (530 g) was evaporated, and the residue was subjected to polyamide column chromatography, eluting with CH₃COCH₃ and then 70% EtOH. The 70% EtOH fraction (260 g) was further separated by silica gel CC, eluting with CH₂Cl₂-MeOH (30 : 1–50 : 50, *V/V*), yielding thirteen fractions (E₁–E₁₃). Fraction E₇ (23.5 g) was separated by ODS CC (30%–100%, MeOH-H₂O) into eight subfractions (E_{7.1}–E_{7.8}). Subfraction E_{7.3} (284 mg) was further purified by preparative HPLC (YMC-ODS-A 5 μm, 250 mm × 20 mm, detection at 210 nm) using CH₃OH-H₂O containing 0.01% TFA (76 : 24, *V/V*, 7 mL·min⁻¹) as the mobile phase to yield compounds **7** (14.8 mg, *t*_R = 82.6 min) and **8** (40 mg, *t*_R = 143.8 min). Subfraction E_{7.6} (550 mg) was purified by preparative HPLC (YMC-ODS-A 5 μm, 250 mm × 20 mm, detection at 210 nm) using CH₃CN-H₂O containing 0.01% TFA (51 : 49, *V/V*, 7 mL·min⁻¹) as the mobile phase, yielding compounds **4** (18.5 mg, *t*_R = 51.6 min), **9** (4.6 mg, *t*_R = 73.5 min), and **10** (15.2 mg, *t*_R = 126.2 min). Subfraction E_{7.7} (485 mg) was subjected to preparative HPLC (YMC-ODS-A 5 μm, 250 mm × 20 mm, detection at 210 nm) using CH₃CN-H₂O containing 0.01% TFA (52 : 48, *V/V*, 7 mL·min⁻¹) as the mobile phase, yielding compounds **2** (22.4 mg, *t*_R = 48.9 min) and **3** (100 mg, *t*_R = 67.2 min). Fraction E₉ (18.2 g) was separated silica gel CC and eluted with CH₂Cl₂-MeOH (12 : 1–5 : 1, *V/V*), affording four subfractions (E_{9.1}–E_{9.4}). Subfraction E_{9.3} (118 mg) was further purified by reversed-phase HPLC using 42% CH₃CN-H₂O containing 0.01% TFA (42 : 58, *V/V*) as the mobile phase, yielding compounds **5** (10.3 mg, *t*_R = 105.4 min) and **6** (8.7 mg, *t*_R = 127.8 min). Fraction E₁₀ (10.4 g) was subjected to silica gel CC and eluted with CH₂Cl₂-MeOH (10 : 1–5 : 1, *V/V*), yielding three fractions (E_{10.1}–E_{10.3}). Subfraction E_{10.3} (160 mg) was further separated by preparative HPLC (YMC-ODS-A 5 μm, 250 mm × 20 mm, detection at 210 nm) using CH₃OH-H₂O containing 0.01% TFA (76 : 24, *V/V*, 7 mL·min⁻¹) as the mobile phase, yielding compound **1** (12.3 mg, *t*_R = 134.6 min).

Cyclocarysaponins A (**1**)

White amorphous powder: $[\alpha]_D^{20}$ -14.8 (*c* 0.08, MeOH); UV (MeOH) λ_{\max} (log ϵ): 200.2 (0.63) nm; IR: 3 437.3, 2 959.9, 1 746.1, 1 644.4, 1 453.6, 1 387.9, 1 247.3, 1 166.6, 1 065.7, 980.3, 896.5, 668.3 cm⁻¹; ¹H NMR (600 MHz, pyridine-*d*₅) and ¹³C NMR (150 MHz, pyridine-*d*₅) (Tables 1 and 2); HR-TOF-MS *m/z* 745.4489 [M + Na]⁺ (Calcd. for C₄₀H₆₆O₁₁Na, 745.4503).

Cyclocarysaponins B (**2**)

White amorphous powder: $[\alpha]_D^{20}$ -19.3 (*c* 0.09, MeOH); UV (MeOH) λ_{\max} (log ϵ): 201.0 (0.93) nm; IR: 3 438.0, 2 943.7, 1 907.0, 1 452.0, 1 367.5, 1 245.0, 1 167.6, 1 065.9, 1 007.0, 980.2, 894.7, 668.4 cm⁻¹; ¹H NMR (600 MHz, pyrid-

ine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 787.4644 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{42}\text{H}_{68}\text{O}_{12}\text{Na}$, 787.4608).

Cyclocarysaponins C (3)

White amorphous powder: $[\alpha]_D^{20}$ -16.4 (c 0.11, MeOH); UV (MeOH) λ_{max} (log ϵ): 201.0 (0.57) nm; IR: 3 423.2, 2 960.0, 1 725.0, 1 453.4, 1 371.4, 1 246.3, 1 166.6, 1 065.4, 979.2, 885.5, 668.5 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 801.4800 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{43}\text{H}_{70}\text{O}_{12}\text{Na}$, 801.4765).

Cyclocarysaponins D (4)

White amorphous powder: $[\alpha]_D^{20}$ -34.8 (c 0.15, MeOH); UV (MeOH) λ_{max} (log ϵ): 201.2 (1.40) nm; IR: 3 416.3, 2 960.7, 1 725.3, 1 674.6, 1 452.4, 1 381.1, 1 248.5, 1 204.6, 1 167.7, 1 065.3, 1 006.9, 980.5, 892.7, 802.5, 722.4, 598.0 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 803.4945 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{43}\text{H}_{72}\text{O}_{12}\text{Na}$, 803.4921).

Cyclocarysaponins E (5)

White amorphous powder: $[\alpha]_D^{20}$ -8.4 (c 0.06, MeOH); UV (MeOH) λ_{max} (log ϵ): 201.2 (0.84) nm; IR: 3 416.0, 2 929.7, 1 726.2, 1 649.2, 1 451.7, 1 388.8, 1 308.2, 1 246.8, 1 166.6, 1 064.9, 980.9, 893.8, 804.9, 554.7 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 803.4566 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{42}\text{H}_{68}\text{O}_{13}\text{Na}$, 803.4558).

Cyclocarysaponins F (6)

White amorphous powder: $[\alpha]_D^{20}$ -4.8 (c 0.07, MeOH); UV (MeOH) λ_{max} (log ϵ): 200.4 (0.62) nm; IR: 3 405.6, 2 957.6, 2 876.0, 1 724.8, 1 649.2, 1 451.7, 1 388.8, 1 308.2, 1 246.8, 1 167.0, 1 065.1, 1 007.0, 980.6, 896.2, 806.3, 668.5 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 789.4410 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{41}\text{H}_{66}\text{O}_{13}\text{Na}$, 789.4401).

Cyclocarysaponins G (7)

White amorphous powder: $[\alpha]_D^{20}$ $+25.4$ (c 0.06, MeOH); UV (MeOH) λ_{max} (log ϵ): 201.0 (0.59) nm; IR: 3 416.5, 2 959.8, 1 725.8, 1 650.0, 1 452.0, 1 389.2, 1 247.7, 1 167.2, 1 065.1, 980.8, 896.2, 668.6 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 629.4033 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{35}\text{H}_{58}\text{O}_8\text{Na}$, 629.4029).

Cyclocarysaponins H (8)

White amorphous powder: $[\alpha]_D^{20}$ -11.7 (c 0.05, MeOH); UV (MeOH) λ_{max} (log ϵ): 200.0 (0.28) nm; IR: 3 409.6, 2 966.7, 1 706.2, 1 453.3, 1 379.6, 1 279.7, 1 169.4, 1 066.8, 1 007.8, 971.7, 891.4, 635.7 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HRTOFMS m/z 719.4003 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{37}\text{H}_{60}\text{O}_{12}\text{Na}$, 719.3982).

Cyclocarysaponins I (9)

White amorphous powder: $[\alpha]_D^{20}$ $+18.8$ (c 0.08, MeOH); UV (MeOH) λ_{max} (log ϵ): 200.8 (0.69) nm; IR: 3 404.6, 2 959.2, 1 657.6, 1 453.6, 1 389.0, 1 318.3, 1 255.8, 1 208.9,

1 166.7, 1 065.9, 978.5, 884.3, 808.1, 637.5 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z 559.3244 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{30}\text{H}_{48}\text{O}_8\text{Na}$, 559.3247).

Cyclocarysaponins J (10)

White amorphous powder: $[\alpha]_D^{20}$ $+21.6$ (c 0.10, MeOH); UV (MeOH) λ_{max} (log ϵ): 202.2 (1.45) nm; IR: 3 411.6, 2 967.2, 1 676.7, 1 455.6, 1 388.5, 1 203.2, 1 139.3, 1 067.1, 945.7, 893.8, 840.7, 800.8, 781.5, 721.4, 668.7 cm^{-1} ; ^1H NMR (600 MHz, pyridine- d_5) and ^{13}C NMR (150 MHz, pyridine- d_5) (Tables 1 and 2); HR-TOF-MS m/z : 559.3267 $[\text{M} + \text{Na}]^+$ (Calcd. for $\text{C}_{30}\text{H}_{48}\text{O}_8\text{Na}$, 559.3247).

Acid hydrolysis and sugar analysis

Based on the reported procedure [23-25], each (2 mg) of compounds **1–10** was dissolved in 2 mol·L $^{-1}$ HCl (dioxane- H_2O , 1 : 1, V/V) and refluxed for 10 h. After removal of the HCl by evaporation until dryness, the residue was suspended in water (2 mL) and then extracted with EtOAc. The remaining aqueous solution was evaporated and dried under reduced pressure to obtain a monosaccharide residue. The residue was dissolved in pyridine (1 mL), followed by the addition of 2 mg L-cysteine methyl ester hydrochloride. The mixture was heated at 60 °C for 2 h, evaporated under an N_2 stream, dried *in vacuo*, and then trimethylsilylated with *N*-trimethylsilylimidazole (0.2 mL) for 2 h. The resulting mixture was partitioned between *n*-hexane and H_2O (2 mL each), and the *n*-hexane soluble layer was analyzed using GC under the following conditions: capillary column, HP-5 (30 m \times 0.32 mm \times 0.25 μm , Agilent); column temperature, 230 °C; injection temperature, 250 °C; flow rate, 1.0 mL·min $^{-1}$; carrier gas, N_2 . The peaks corresponding to D-quinovose (12.8 min) were detected in the hydrolysate of compounds **3–5** and **7–9**, those corresponding to L-arabinofuranose (9.8 and 10.4 min) were observed in the hydrolysates of compounds **2–6**, **8**, and those corresponding to L-arabinopyranose (10.7 and 10.9 min) were detected in the hydrolysates of compounds **1**, **2**, **6**, **10**.

Evaluation of bioactivity

Cytotoxicity evaluation

The cytotoxicity assay was performed against five human tumor cell lines: Bel-7402 (human hepatoma cancer cell line), Caski (human cervical cancer cell line), BGC-823 (human gastric cancer cell line), A2780 (human ovarian cancer cell line), and HCT-116 (human colon cancer cell line). All the cell lines were purchased from FengHuiShengWu (Hunan, China). The cells were maintained in RPMI-1640 complete medium (WH1122G081, Yuchun Biolog, Shanghai, China) supplemented with 10% FBS and 1% P/S solution. Then the cells were incubated at 37 °C in a humidified atmosphere with 5% CO_2 . During the experiments, cells in the exponential growth phase were sub-cultured twice a week. Compounds **1–10** were dissolved in 0.5% DMSO and RPMI-1640 complete medium to prepare stock solutions, which were stored at 4 °C. Cells were cultured in 96-well plates at a density of 1×10^4 cells per well in 100 μL of the medium. After cultivation for 24 h, cells were treated with 100 μL of

test compounds and incubated for 48 h. Then, 10 μ L CCK-8 (Cell Counting Kit-8) solution was added to each well, and the plates were incubated for 4 h. Absorbance was measured at 450 nm using a microplate reader [26-28].

Enzyme inhibition assay

The inhibitory activities of compounds **1–10** against the enzymatic activity of α -glucosidase and PTP1B were evaluated according to the previously described method [29, 30].

Anti-inflammatory activity

The anti-inflammatory activity of compounds **1–10** was assessed by measuring the NO production in LPS-induced RAW 264.7 mouse macrophages (positive control, dexamethasone), according to the previously described method [31].

Supporting Information

Supporting information can be requested by sending E-mail to the corresponding authors.

References

- [1] Shu RG, Xu CR, Li LN, et al. Cyclocariosides II and III: two seco-dammarane triterpenoid saponins from *Cyclocarya paliurus* [J]. *Planta Med*, 1995, **61**(6): 551-554.
- [2] Fang SZ, Wang JY, Wei ZY, et al. Methods to break seed dormancy in *Cyclocarya paliurus* (Batal.) Iljinskaja [J]. *Sci Horticulture-amsterdam*, 2006, **110**(3): 305-309.
- [3] Kennelly EJ, Cai LN, Long LN, et al. Novel highly sweet seco-dammarane glycosides from *Pterocarya paliurus* [J]. *J Agric Food Chem*, 1995, **43**(10): 2602-2607.
- [4] Zhao XX, Ji YL, Zhu LP, et al. Arjunolic acid from *Cyclocarya paliurus* ameliorates diabetic retinopathy through AMPK/mTOR/HO-1 regulated autophagy pathway [J]. *J Ethnopharmacol*, 2022, **284**: 114772.
- [5] Peng HM, He XJ, Chen JX, et al. Hypoglycemic effects of extracts of *Cyclocarya paliurus* (Batal.) Iljinskaja for experimental diabetic model mice [J]. *J Sichuan Trad Chin Med*, 2018, **36**: 60-63.
- [6] Xiao HT, Wen B, Ning ZW, et al. *Cyclocarya paliurus* tea leaves enhances pancreatic β cell preservation through inhibition of apoptosis [J]. *Sci Rep*, 2020, **10**(1): 19446.
- [7] Zhao LC, Wang X, Li JX, et al. Effect of *Cyclocarya paliurus* on hypoglycemic effect in type 2 diabetic mice [J]. *Med Sci Monit*, 2019, **25**: 2976-2983.
- [8] Tong YP, Li X, Zhu ZP, et al. Extraction and identification of antioxidant ingredients from *Cyclocarya paliurus* (Batal.) Iljinsk using UHPLC-Q-Orbitrap-MS/MS-based molecular networking [J]. *J Chem*, 2022, **2022**: 1-14.
- [9] Chen ZL, Jian YQ, Wu Q, et al. *Cyclocarya paliurus* (Batalin) Iljinskaja: botany, ethnopharmacology, phytochemistry and pharmacology [J]. *J Ethnopharmacol*, 2022, **285**: 114912.
- [10] Chen ZL, Wu Q, Wu J, et al. Qingqianlianus A–N, 3, 4-seco-dammarane triterpenoids from the leaves of *Cyclocarya paliurus* and their biological activities [J]. *Arab J Chem*, 2023, **16**: 104441.
- [11] Shu RG, Wu CR, Li LN. Studies on the sweet principles from the leaves of *Cyclocarya Paliurus* (Batal.) Iljinsk [J]. *Acta Pharm Sin*, 1995, **30**(10): 757-761.
- [12] Yang DJ, Zhong ZC, Xie ZM. Studies on the sweet principles from the leaves of *Cyclocarya paliurus* (Batal.) Iljinskaja [J]. *Acta Pharm Sin*, 1992, **27**(11): 841-844.
- [13] Li SB, Xian XY, Peng CF, et al. Two new dammarane triterpenoid saponins from the leaves of *Cyclocarya paliurus* [J]. *J Asian Nat Prod Res*, 2022, **25**(5): 438-445.
- [14] Zhou XL, Li SB, Yan MQ, et al. Bioactive dammarane triterpenoid saponins from the leaves of *Cyclocarya paliurus* [J]. *Phytochemistry*, 2021, **183**: 112618.
- [15] Zhu LP, Yang HM, Zheng X, et al. Four new dammarane triterpenoid glycosides from the leaves of *Cyclocarya paliurus* and their SIRT1 activation activities [J]. *Fitoterapia*, 2021, **154**: 105003.
- [16] Liu W, Deng SP, Zhou DX, et al. 3, 4-seco-Dammarane triterpenoid saponins with anti-inflammatory activity isolated from the leaves of *Cyclocarya paliurus* [J]. *J Agric Food Chem*, 2020, **68**(7): 2041-2053.
- [17] Lin Z, Wu ZF, Jiang CH, et al. The chloroform extract of *Cyclocarya paliurus* attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats [J]. *Phytomedicine*, 2016, **23**(12): 1475-1483.
- [18] Wu ZF, Meng FC, Cao LJ, et al. Triterpenoids from *Cyclocarya paliurus* and their inhibitory effect on the secretion of apolipoprotein B48 in Caco-2 cells [J]. *Phytochemistry*, 2017, **142**: 76-84.
- [19] Chen YJ, Na L, Fan JL, et al. Seco-dammarane triterpenoids from the leaves of *Cyclocarya paliurus* [J]. *Phytochemistry*, 2018, **145**: 85-92.
- [20] Xuan TY, Tan J, Sun HH, et al. Cyclocarioside O–Q, three novel seco-dammarane triterpenoid glycosides from the leaves of *Cyclocarya paliurus* [J]. *Nat Prod Res*, 2021, **35**(1): 167-173.
- [21] Wu Y, Li YY, Wu X, et al. Chemical constituents from *Cyclocarya paliurus* (Batal.) Iljinsk [J]. *Biochem Syst Ecol*, 2014, **57**: 216-220.
- [22] Li CG, Deng SP, Liu W, et al. α -Glucosidase inhibitory and anti-inflammatory activities of dammarane triterpenoids from the leaves of *Cyclocarya paliurus* [J]. *Bioorg Chem*, 2021, **111**: 104847.
- [23] Ün RN, Masullo M, Karayildirim T, et al. Triterpene glycosides from *Silene odontopetala* [J]. *Phytochemistry*, 2020, **176**: 112404.
- [24] Ono M, Yuhara N, Shimohara T, et al. Calyhedins I–VI: resin glycosides from the rhizomes of *Calystegia hederacea* [J]. *Phytochemistry*, 2021, **190**: 112888.
- [25] Liu X, Wang Y, Alizade V, et al. Cruciasides C–G, monoterpenoid glycosides from *Cruciata articulata* [J]. *Phytochemistry*, 2021, **189**: 112821.
- [26] Jin X, Sun PP, Hong Y, et al. Puerarin induces apoptosis in A549 cells [J]. *Chin J Appl Physiol*, 2017, **33**(5): 466-469.
- [27] Zhang W, Han D. miR-185-3p targets Annexin-A8 to inhibit proliferation in cervical cancer cells [J]. *Cytotechnology*, 2021, **73**(4): 585-592.
- [28] Zhang WH, Zhang ML, Jing WW, et al. Inhibitory effect of CCK-8 on methamphetamine-induced apoptosis [J]. *J Forensic Med*, 2021, **37**(6): 796-805.
- [29] Yang F, Zhu W, Sun S, et al. Isolation and structural characterization of specific bacterial β -glucuronidase inhibitors from Noni (*Morinda citrifolia*) fruits [J]. *J Nat Prod*, 2020, **83**: 825-833.
- [30] Uddin MN, Sharma G, Yang JL, et al. Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from *Camellia japonica* [J]. *Phytochemistry*, 2014, **103**: 99-106.
- [31] Li H, Zhao JJ, Chen JL, et al. Diterpenoids from aerial parts of *Flickingeria fimbriata* and their nuclear factor-kappa-B inhibitory activities [J]. *Phytochemistry*, 2015, **117**: 400-409.

Cite this article as: XI Huiting, YUAN Mingming, XIE Jianhua, et al. Cyclocarysaponins A–J, dammarane-type triterpenoid glycosides from the leaves of *Cyclocarya paliurus* [J]. *Chin J Nat Med*, 2024, **22**(10): 955-964.